| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444351 | European Journal of Cancer | 2013 | 10 Pages |
Abstract
The RR of 52% in REAL3 with mEOCÂ +Â P met pre-defined criteria to continue accrual to phase III. The frequency of the mutations was too low to exclude any prognostic or predictive effect.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
A.F.C. Okines, D. Gonzalez de Castro, D. Cunningham, I. Chau, R.E. Langley, L.C. Thompson, S.P. Stenning, C. Saffery, Y. Barbachano, F. Coxon, G. Middleton, D. Ferry, T. Crosby, S. Madhusudan, J. Wadsley, J. Waters, M. Hall, D. Swinson, A. Wotherspoon,